Mibg (123i) Curium Netherlands

Iobenguane (I-123), the active ingredient in Mibg (123i) Curium Netherlands, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is used for diagnostic imaging of cardiac sympathetic innervation, pheochromocytoma, and neuroblastoma in patients requiring functional assessment.

GNH USA supplies Mibg (123i) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Iobenguane (I-123) is employed in nuclear medicine to visualize sympathetic nerve activity and catecholamine‑producing tumors. - Cardiac sympathetic innervation imaging: enables assessment of myocardial sympathetic nerve function in heart failure patients. - Pheochromocytoma detection: identifies catecholamine‑secreting adrenal tumors for pre‑operative planning. - Neuroblastoma imaging: visualizes neuroblastoma lesions to aid staging and treatment monitoring.

Adverse reactions may occur following administration of Iobenguane I-123.

Common Side Effects: - Nausea: mild, transient discomfort. - Headache: mild to moderate intensity. - Flushing: brief skin reddening. - Injection site pain: localized discomfort. - Transient hypertension: temporary rise in blood pressure. - Dizziness: mild vertigo.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure. - Radiation‑induced thyroid dysfunction: potential alteration of thyroid hormone levels. - Cardiac arrhythmia: irregular heart rhythm. - Pulmonary edema: fluid accumulation in lungs. - Radiation‑induced malignancy: extremely rare long‑term risk.

Use of Iobenguane I-123 requires careful consideration of patient factors and handling procedures. - Pregnancy: risk unknown; avoid unless essential. - Breastfeeding: risk unknown; consider discontinuing breastfeeding. - Renal impairment: monitor renal function and adjust imaging schedule if needed. - Thyroid blocking: assess need for iodine prophylaxis to reduce thyroid uptake. - Hypersensitivity: contraindicated in patients with known allergy to the radiotracer. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iobenguane I-123 may interact with drugs affecting norepinephrine pathways or radiation exposure.

Major Interactions (Avoid): - Reserpine or guanethidine: reduce tracer uptake. - Potassium iodide or other thyroid blocking agents: interfere with thyroid imaging. - High‑dose catecholamines: compete for NET transport. - Concurrent I‑123 radiopharmaceuticals: increase cumulative radiation dose. - MAO inhibitors: may alter catecholamine metabolism.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may affect hemodynamic response. - Sympathomimetic agents (e.g., epinephrine): alter tracer distribution. - Diuretics: influence renal clearance of the tracer. - Iodinated contrast agents: may affect image interpretation. - Other diagnostic radiopharmaceuticals: require dose timing adjustments.